LearnGlossaryMarketStocksSuperinvestorsSign in

EYPT

EyePoint Pharmaceuticals, Inc.

Healthcare · $274M market cap

Verdict

We can't put a fair value on EYPT right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth-7.3% a year✗
Equity per share growth-10.1% a year✗
Sales growth11.4% a year✓
Free cash flow growth0.5% a year✗
Return on invested capital-46.4%✗

Follow EYPT

Track it on your watchlist and see the full analysis. Free.

Create a free account

About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works